New York State Common Retirement Fund’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.42M | Buy |
171,712
+43,593
| +34% | +$896K | 0.01% | 1127 |
|
|
2026
Q1 | $2.46M | Buy |
128,119
+89,641
| +233% | +$1.78M | ﹤0.01% | 1305 |
|
|
2025
Q4 | $635K | Hold |
38,478
| – | – | ﹤0.01% | 1877 |
|
|
2025
Q3 | $559K | Hold |
38,478
| – | – | ﹤0.01% | 1904 |
|
|
2025
Q2 | $538K | Sell |
38,478
-31,762
| -45% | -$447K | ﹤0.01% | 1884 |
|
|
2025
Q1 | $955K | Sell |
70,240
-74,484
| -51% | -$1.43M | ﹤0.01% | 1648 |
|
|
2024
Q4 | $2.95M | Sell |
144,724
-5,184
| -3% | -$133K | ﹤0.01% | 1281 |
|
|
2024
Q3 | $4.37M | Sell |
149,908
-14,037
| -9% | -$348K | 0.01% | 1156 |
|
|
2024
Q2 | $3.81M | Buy |
163,945
+38,170
| +30% | +$733K | 0.01% | 1241 |
|
|
2024
Q1 | $2.58M | Buy |
125,775
+1,801
| +1% | +$33.8K | ﹤0.01% | 1373 |
|
|
2023
Q4 | $2.66M | Sell |
123,974
-5,879
| -5% | -$116K | ﹤0.01% | 1349 |
|
|
2023
Q3 | $2.68M | Buy |
129,853
+3,954
| +3% | +$100K | ﹤0.01% | 1340 |
|
|
2023
Q2 | $3.72M | Sell |
125,899
-8,995
| -7% | -$253K | ﹤0.01% | 1283 |
|
|
2023
Q1 | $3.11M | Sell |
134,894
-16,060
| -11% | -$442K | ﹤0.01% | 1359 |
|
|
2022
Q4 | $4.2M | Buy |
150,954
+6,049
| +4% | +$180K | 0.01% | 1259 |
|
|
2022
Q3 | $4.45M | Buy |
144,905
+4,076
| +3% | +$133K | 0.01% | 1213 |
|
|
2022
Q2 | $4.14M | Buy |
140,829
+5,988
| +4% | +$157K | 0.01% | 1286 |
|
|
2022
Q1 | $4.34M | Buy |
134,841
+54
| +0% | +$1.86K | ﹤0.01% | 1344 |
|
|
2021
Q4 | $6.01M | Sell |
134,787
-22,106
| -14% | -$1.05M | 0.01% | 1219 |
|
|
2021
Q3 | $7.92M | Sell |
156,893
-23,368
| -13% | -$1.32M | 0.01% | 1110 |
|
|
2021
Q2 | $14.1M | Buy |
180,261
+33,358
| +23% | +$2.06M | 0.01% | 835 |
|
|
2021
Q1 | $8.39M | Buy |
146,903
+9,605
| +7% | +$643K | 0.01% | 1046 |
|
|
2020
Q4 | $11.5M | Buy |
137,298
+58,198
| +74% | +$3.52M | 0.01% | 868 |
|
|
2020
Q3 | $2.83M | Buy |
79,100
+21,500
| +37% | +$648K | ﹤0.01% | 1400 |
|
|
2020
Q2 | $1.39M | Buy |
57,600
+14,800
| +35% | +$348K | ﹤0.01% | 1706 |
|
|
2020
Q1 | $749K | Hold |
42,800
| – | – | ﹤0.01% | 1855 |
|
|
2019
Q4 | $746K | Sell |
42,800
-6,800
| -14% | -$113K | ﹤0.01% | 2093 |
|
|
2019
Q3 | $760K | Hold |
49,600
| – | – | ﹤0.01% | 2119 |
|
|
2019
Q2 | $1.03M | Sell |
49,600
-8,220
| -14% | -$184K | ﹤0.01% | 2004 |
|
|
2019
Q1 | $1.34M | Buy |
57,820
+13,120
| +29% | +$274K | ﹤0.01% | 1807 |
|
|
2018
Q4 | $924K | Buy |
44,700
+23,900
| +115% | +$434K | ﹤0.01% | 1958 |
|
|
2018
Q3 | $452K | Hold |
20,800
| – | – | ﹤0.01% | 2460 |
|
|
2018
Q2 | $317K | Buy |
20,800
+12,000
| +136% | +$226K | ﹤0.01% | 2654 |
|
|
2018
Q1 | $173K | Buy |
+8,800
| New | +$181K | ﹤0.01% | 2792 |
|
Other funds holding DNLI
New York State Common Retirement Fund's DNLI Position: Q2 2026 in Review
New York State Common Retirement Fund increased its Denali Therapeutics (DNLI) stake by 34% in Q2 2026, buying an estimated $896K and bringing the position to 171,712 shares worth $4.42M. The position accounts for 0.01% of the portfolio, ranked #1127.
New York State Common Retirement Fund first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $14.1M in Q2 2021. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- New York State Common Retirement Fund held 171,712 shares of Denali Therapeutics worth $4.42M as of Q2 2026.
- New York State Common Retirement Fund bought 43,593 Denali Therapeutics shares in Q2 2026, an estimated $896K.
- Denali Therapeutics made up 0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1127 holding.
- New York State Common Retirement Fund first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- New York State Common Retirement Fund's Denali Therapeutics position peaked at $14.1M in Q2 2021.
- 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.